Benitec Biopharma
BNTC
3 hedge funds and large institutions have $55K invested in Benitec Biopharma in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
26% less capital invested
Capital invested by funds: $74K → $55K (-$19K)
40% less funds holding
Funds holding: 5 → 3 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.87K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$5.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$18.7K |
| 2 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$13K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$8K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WS
1
Wedbush Securities
Los Angeles,
California
| $39K | -$18.7K | -35 | -33% |
|
|
2
UBS Group
Zurich,
Switzerland
| $10K | +$5.87K | +11 | +183% |
|
|
3
Bank of America
Charlotte,
North Carolina
| $6K | +$5.34K | +10 | New |
|
|
AIM
4
Acrospire Investment Management
Chicago,
Illinois
| – | -$13K | -28 | Closed |
|
|
5
Acadian Asset Management
Boston,
Massachusetts
| – | -$8K | -16 | Closed |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1K | -4 | Closed |
|
BNTC Hedge Fund Activity: Q3 2017 in Review
3 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2017, worth a combined $55K — down 26% from $74K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BNTC and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $5.87K. The largest seller was Wedbush Securities, cutting an estimated $18.7K.
- 3 institutional investors held Benitec Biopharma (BNTC) as of Q3 2017, down from 5 in Q2 2017.
- Funds reported $55K of Benitec Biopharma stock for Q3 2017, down 26% quarter-over-quarter.
- 1 fund opened new Benitec Biopharma positions in Q3 2017 and 3 closed out, a net change of -2 holders.
- The largest Benitec Biopharma buyer in Q3 2017 was UBS Group, an estimated $5.87K added.
- The largest Benitec Biopharma seller in Q3 2017 was Wedbush Securities, an estimated $18.7K sold.
Based on aggregated 13F filings for Q3 2017.